Stock Track | ImmuneOnco Soars on Leukemia Drug's Phase 3 Trial Initiation

Stock Track11-12

Shares of ImmuneOnco Biopharmaceuticals (Shanghai) Co. Ltd. (HKG:01541) surged 18.66% on Monday after the company announced a major clinical milestone for its lead drug candidate IMM01.

The Chinese biotech firm dosed the first patient in a Phase 3 clinical trial evaluating IMM01 (Timdarpacept) in combination with azacitidine for the first-line treatment of chronic myelomonocytic leukemia (CMML), a type of rare blood cancer.

Initiation of this late-stage study marks an important inflection point for IMM01's clinical development program. Positive data from the Phase 3 trial would support regulatory submissions for the drug candidate as a potential new treatment option for CMML patients worldwide.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1125715818?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-12 20:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1125715818","market":"us","top_or_hot":-1,"title":"Stock Track | ImmuneOnco Soars on Leukemia Drug's Phase 3 Trial Initiation","media":"Stock Track","content":"<p>Shares of ImmuneOnco Biopharmaceuticals (Shanghai) Co. Ltd. (HKG:01541) surged 18.66% on Monday after the company announced a major clinical milestone for its lead drug candidate IMM01.</p>\n\n<p>The Chinese biotech firm dosed the first patient in a Phase 3 clinical trial evaluating IMM01 (Timdarpacept) in combination with azacitidine for the first-line treatment of chronic myelomonocytic leukemia (CMML), a type of rare blood cancer.</p>\n\n<p>Initiation of this late-stage study marks an important inflection point for IMM01's clinical development program. Positive data from the Phase 3 trial would support regulatory submissions for the drug candidate as a potential new treatment option for CMML patients worldwide.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | ImmuneOnco Soars on Leukemia Drug's Phase 3 Trial Initiation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | ImmuneOnco Soars on Leukemia Drug's Phase 3 Trial Initiation\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-12 20:04 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of ImmuneOnco Biopharmaceuticals (Shanghai) Co. Ltd. (HKG:01541) surged 18.66% on Monday after the company announced a major clinical milestone for its lead drug candidate IMM01.\nThe Chinese ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01541","symbol_name":"宜明昂科-B","start_time":0,"source_url":"","article_id":"1125715818","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1125715818","pubTimestamp":1731413063,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of ImmuneOnco Biopharmaceuticals  Co. Ltd.  surged 18.66% on Monday after the company announced a major clinical milestone for its lead drug candidate IMM01.The Chinese biotech firm dosed the first patient in a Phase 3 clinical trial evaluating IMM01  in combination with azacitidine for the first-line treatment of chronic myelomonocytic leukemia , a type of rare blood cancer.Initiation of this late-stage study marks an important inflection point for IMM01's clinical development program. P","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01541":"宜明昂科-B"},"translate_title":"白血病药物3期试验启动，股票追踪ImmuneOnco股价飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01541":1},"content_text":"Shares of ImmuneOnco Biopharmaceuticals (Shanghai) Co. Ltd. (HKG:01541) surged 18.66% on Monday after the company announced a major clinical milestone for its lead drug candidate IMM01.\nThe Chinese biotech firm dosed the first patient in a Phase 3 clinical trial evaluating IMM01 (Timdarpacept) in combination with azacitidine for the first-line treatment of chronic myelomonocytic leukemia (CMML), a type of rare blood cancer.\nInitiation of this late-stage study marks an important inflection point for IMM01's clinical development program. Positive data from the Phase 3 trial would support regulatory submissions for the drug candidate as a potential new treatment option for CMML patients worldwide.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1125715818"}